ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Orion Genomics Announces The Discovery Of Novel Breast Cancer Biomarkers
Orion Genomics announced the
discovery and validation of the most frequent DNA alterations detected in
breast cancer to date. The results of a genome wide analysis of DNA
methylation appeared in PLoS ONE. The study entitled, "Identification of
Novel High Frequency DNA Methylation Changes in Breast Cancer" found more
than 50 novel biomarkers, which were subsequently validated in up to 230
independent patient samples.
"Our study identified novel biomarkers that were individually capable
of distinguishing early stage ductal breast cancer from normal and benign
breast tissue," commented Jared Ordway, Ph.D., Director of Research and
Development at Orion Genomics. "We are very excited about the potential of
these findings as these biomarkers may be critical in the development of
molecular diagnostics for the early detection of breast cancer."
Researchers applied a patented microarray-based approach to map tumor
associated changes in DNA methylation, alterations that can affect normal
gene expression. A single locus associated with the GHSR gene was the most
powerful biomarker in the study, with a clinical sensitivity of 90% and a
specificity of 96% for infiltrating ductal breast carcinoma. In addition to
identifying biomarkers that might aid in the detection of breast cancer,
the research revealed insights into the molecular mechanism of tumor
development, which may lead to advances in breast cancer treatment.
"Twelve of our more than fifty breast cancer biomarkers exceeded the
highest sensitivity previously reported for the stratification of tumor and
normal tissue," added Nathan D. Lakey, President and CEO of Orion Genomics.
"These results validate our biomarker discovery platform and our product
pipeline, which is focused on breast, lung and ovarian cancer diagnostics."
About Orion Genomics
Orion Genomics, the Second Code biotechnology company, develops genomic
research tools and molecular diagnostic products to detect cancer at its
earliest stages and to aid in appropriate therapy selection. The company
has active biomarker discovery programs in cancers of the bladder, breast,
lung, ovaries and colon. Orion Genomics is located in the Center for
Emerging Technologies in St. Louis. For more information, visit
http://www.oriongenomics.com.
Orion Genomics
http://www.oriongenomics.com
Orion genomicã anunþã descoperirea Novel cancer de sân biomarkeri - Orion Genomics Announces The Discovery Of Novel Breast Cancer Biomarkers - articole medicale engleza - startsanatate